Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry

Lung Cancer

Volumn 40, Issue 3, 2003, Pages 267-279

  Zhukov, Tatyana A ^a   Johanson, Roy A ^b   Cantor, Alan B ^a   Clark, Robert A ^a   Tockman, Melvyn S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b CIPHERGEN BIOSYSTEMS INC   (United States)

Author keywords

Early lung cancer; Proteomics; SELDI mass spectrometry

Indexed keywords

TUMOR PROTEIN;

ADENOMA; CANCER DIAGNOSIS; CANCER SCREENING; CELL POPULATION; CELL TYPE; CONFERENCE PAPER; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; EPITHELIUM CELL; FEASIBILITY STUDY; FROZEN SECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LASER; LUNG; LUNG CANCER; LUNG TUMOR; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MASS SPECTROMETRY; MOLECULAR WEIGHT; PRECANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; REPRODUCIBILITY; RESPIRATORY EPITHELIUM; TUMOR CELL; VALIDATION PROCESS;

EID: 0037683738     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00082-5     Document Type: Conference Paper

References (32)

1. Smith R.A., Glynn T.J. Epidemiology of lung cancer. Radiol. Clin. North Am. 38:2000;453-470.
2. Hirsch F.R., Franklin W.A., Gazdar A.F., Bunn P.A. Jr. Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin. Cancer Res. 7:2001;5-22.
3. Tockman M.S. Survival and mortality from lung cancer in a screened population - the Johns Hopkins Study. Chest. 89:1986;324S-325S.
4. Henchke C.I., McCauley D.I., Yankelevitz D.F., et al. Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet. 354:1999;99-105.
5. Vazquez M.F., Flieder D.B. Small peripheral glandular lesions detected by screening CT for lung cancer. A diagnostic dilemma for the pathologist. Radiol. Clin. North Am. 38:2000;579-589.
6. Markers of Transformation in Airways Epithelial Cells from a Cohort of Obstructed Smokers and Former Smokers. Ongoing Clinical Trial at the Moffitt Cancer Center, PI. M. Tockman, 2002.
7. Kvale PA. Lung cancer and solitary pulmonary nodule. The ACCP Pulmonary Board Review 2000;157-72.
8. Hirsch F.R., Franklin W.A., Gazdar A.F., Bunn P.A. Jr. Early detection of lung cancer: clinical perspectives of recent advances in biology and radiology. Clin. Cancer Res. 7:2001;5-22.
9. Simone N.L., Bonner R.F., Gillespie J.W., Emmert-Buck M.R., Liotta L.A. Laser-capture microdissection: opening the microscopic frontier to molecular analysis. Elsevier Trends J., Trends Genet. 14:1998;272-276.
10. Hutchens T.W., Yip T.T. New desorption strategies for the mass spectrometric analysis of macromolecules. Rapid Commun. Mass Spectrom. 7:1993;576-580.
11. Wright G.L. Jr, Cazares L.H., Leung S.M., et al. ProteinChip surface enhanced laser desorption/ionization mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer Prostate Dis. 2:1999;264-276.
12. Brambilla E., Travis W.D., Colby T.V., Corrin B., Shimosato Y. The new World Health Organization classification of lung tumours. Eur. Respir. J. 18:2001;1059-1068.
13. Kitamura H., Kameda Y., Ito T., et al. Cytodifferentiation of atypical adenomatous hyperplasia and bronchioloalveolar lung carcinoma: immunohistochemical and ultrastructural studies. Virchows Arch. 431:1997;415-424.
14. Kerr K.M., Carey F.A., King G., Lamb D. Atypical alveolar hyperplasia: relationship with pulmonary adenocarcinoma, p53, and c-erbB-2 expression. J. Pathol. (London). 174:1994;249-256.
15. Nakayama H., Noguchi M., Tsuchiya R., Kodama T., Shimosato Y. Clonal growth of atypical adenomatous hyperplasia of the lung: cytofluorometric analysis of nuclear DNA content. Modern Pathol. 3:1990;314-320.
16. Shimosato Y. Pulmonary neoplasms. Sternberg S.S. Diagnostic surgical pathology. 2nd ed:1994;1045-1093 Raven Press, New York.
17. Emmert-Buck M.R., Bonner R.F., Smith P.D., Chuaqui R.F., et al. Laser capture microdissection. Science (Washington, DC). 274:1996;998-1001.
18. Hanash S., Brichory F., Beer D. A proteomic approach to the identification of lung cancer markers. Disease Mark. 17:2001;295-300.
19. Oh J.M.C., Brichory F., Puravs E., et al. A database of protein expression in lung cancer. Proteomics. 1:2001;1303-1319.
20. Yamamoto A., Shimizu E., Ogura T., Sone S.H. Detection of auto-antibodies against L-myc oncogene products in sera from lung cancer patients. Int. J. Cancer. 22:1996;283-289.
21. Petricoin E.F., Ardekani A.M., Hitt B.A., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 359:2002;572-577.
22. Vlahou A., Schellhammer P.F., Mendrinos S., et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am. J. Pathol. 158:2001;1491-1502.
23. Le Naour F., Misek D.E., Krause M.C., et al. Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin. Cancer Res. 7:2001;3328-3335.
24. Tockman M.S., Gupta P.K., Myers J.D., et al. Sensitive and specific monoclonal antibody recognition of human lung cancer antigen on preserved sputum cells: a new approach to early lung cancer detection. J. Clin. Oncol. 6:1988;1685-1693.
25. Tockman M.S., Mulshine J.L., Piantadosi S. Prospective detection of preclinical lung cancer: results from two studies of heterogeneous nuclear ribonucleoprotein A2/B1 overexpression. Clin. Cancer Res. 3:1997;2237-2246.
26. Tockman M.S., Zhukov T.A., Erozan Y.S., Westra W.H., Zhou J., Mulshine J.L. Antigen retrieval improves hnRNP A2/B1 immunohistochemical localization in premalignant lesions of the lung. Martinet Y., Hirsch F.R., Martinet N., Vignaud J.M., Mulshine J.L. Clinical and biological basis of lung cancer prevention. 1998;239-246 Birkhauser Verlag, Basel, Switzerland.
27. Zhukov TA, Erozan YS, Tockman MS. Sentinel cell for lung cancer. The 14th International Congress of Cytology, Amsterdam, The Netherland, 27-31 May 2001. p. 352.
28. Niklinski J., Niklinska W., Chyczewski L., Becker H.D., Pluygers E. Molecular genetic abnormalities in premalignant lung lesions: biological and clinical implications. Eur. J. Cancer Preven. 10:2001;213-226.
29. Carey F.A., Wallace W.A.H., Fergusson R.J., Kerr K.M., Lamb D. Alveolar atypical hyperplasia in association with primary pulmonary adenocarcinoma: a clinicopathological study of 10 cases. Thorax. 47:1992;1041-1043.
30. Kerr K.M., Carey F.A., King G., Lamb D. Atypical alveolar hyperplasia: relationship with pulmonary adenocarcinoma, p53, and c-erbB-2 expression. J. Pathol. (London). 174:1994;249-256.
31. Yankelevitz D.F., Henschke C.I. Does 2-year stability imply pulmonary nodules are benign? Am. J. Roentgenol. 168:1997;325-328.
32. Liotta L.A., Kohn E.C., Petricoin E.F. Clinical proteomics: personalized molecular medicine. J. Am. Med. Assoc. 286:2001;2211-2214.